Development of multiple sclerosis after vaccination against hepatitis B: A study based on human leucocyte antigen haplotypes

Tissue Antigens

Volumn 68, Issue 3, 2006, Pages 235-238

  Ozakbas S ^a   Idiman, E ^a   Yulug, B ^a   Pakoz, B ^a   Bahar, H ^a   Gulay, Z ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Hepatitis B; HLA haplotypes; Immune response; Multiple sclerosis; Risk factors; Vaccination

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HLA DR2 ANTIGEN;

ADULT; ANTIGEN PRESENTATION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE COURSE; FEMALE; HAPLOTYPE; HEPATITIS B; HLA SYSTEM; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; SEROLOGY; SYMPTOMATOLOGY;

ADOLESCENT; ADULT; FEMALE; HAPLOTYPES; HEPATITIS B; HEPATITIS B VACCINES; HLA-DR2 ANTIGEN; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; VACCINATION;

EID: 33748423252     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00653.x     Document Type: Article

References (33)

1. Hunter SF, Rodrigez M. Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Springer Semin Immunopathol 1995: 17: 89-105.
2. Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol 1994: 36: S15-7.
3. Uria DF. HLA and multiple sclerosis: studies of a Spanish population. Rev Neurol 2000: 31: 1066-70.
4. Saruhan-Direskeneli G, Esin S, Baykan-Kurt B, Örnek İ, Vaughan R, Eraksoy M. HLA-DR and DQ associations with multiple sclerosis in Turkey. Human Immunol 1997: 55: 59-65.
5. Donmez B, Ozakbas S, Oktem MA et al. HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features. Human Immunol 2004: 65:752-7.
6. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995: 13: S47-9.
7. Shaw FE Jr, Graham DJ, Guess HA et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination: experience of the first three years. Am J Epidemiol 1988: 127: 337-52.
8. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992: 92: 254-6.
9. Gout O, Théodorou I, Liblau R et al. Central nervous system demyelination after recombinant hepatitis B vaccination report of 25 cases. Neurology 1997: 48: A424.
10. Gout O, Lyon-Caen O. Sclérose en plaques et vaccination contre le virus de l'hépatite B. Rev Neurol [Paris] 1998: 154: 205-7.
11. Tourbah A, Gout O, Liblau R et al. Encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? Neurology 1999: 53: 396-401.
12. Herroelen L, de Keyser J, Ebinger G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991: 338: 1174-5.
13. Iniguez C, Mauri JA, Larrode P, Lopez del Val J, Jerico I, Morales F. Acute transverse myelitis secondary to hepatitis B vaccination. Rev Neurol 2000: 31: 430-2.
14. Trevisani F, Gattinara GC, Caraceni P et al. Transversemyelitis following hepatitis B vaccination. J Hepatol 1993: 19: 317-8.
15. Kaplanski G, Retornaz F, Durand J, Soubeyrand J. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype. J Neurol Neurosurg Psychiatr 1995: 58: 758-9.
16. Voigt U, Baum U, Behrendt W, Hegemann S, Terborg C, Strobel J. Neuritis of the optic nerve after vaccinations against hepatitis A, hepatitis B and yellow fever. Klin Monatsbl Augenheilkd 2001: 218: 688-90.
17. Craven DE, Awdeh ZL, Kunches LM et al. Nonresponsiveness to hepatitis B vaccine in health careworkers. Ann Intern Med 1986: 105: 356-60.
18. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, Ettenger RB. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988: 260: 1734-8.
19. Alper CA, Kruskall MS, Marcus-Bagley D et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Eng J Med 1989: 321: 708-12.
20. Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H. Genetic basis of nonresponse to hepatitis B vaccine in hemodialyzed patients. J Hepatol 1990: 11: 385-7.
21. Varla-Leftherioti M, Papanicolaou M, Spyropoulou M et al. HLA-associated non-responsiveness to hepatitis B vaccine. Tissue Antigens 1990: 35: 60-3.
22. Watanabe H, Matsuchita S, Kamikawaji N, Hirayama K, Okumura M, Sasazuki T. Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Human Immunol 1988: 22: 9-17.
23. Watanabe H, Okumura M, Hirayama K, Sasazuki T. HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T cells. Tissue Antigens 1990: 36: 69-74.
24. Hatae K, Kimura A, Okubo R et al. Genetic control of nonresponsivenes to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol 1992: 22: 1899-905.
25. Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998: 51: 593-604.
26. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983: 13: 227-31.
27. Barkhoff F, Filippi M, Miller DH. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997: 120: 2059-69.
28. Fujinami RS, Oldstone MA. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 1985: 230: 1043-5.
29. Robinson WS. Hepatitis B virus and hepatitis D virus. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practices of Infectious Diseases, 5th edn. Philadelphia: Churchill Livingstone, 2000.
30. Wucherpfennig KW, Stominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995: 80: 695-705.
31. Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001: 344: 327-32.
32. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S; Vaccines in Multiple Sclerosis Study Group. Vaccination and risk of relapse in multiple sclerosis. N Engl J Med 2001: 344: 319-26.
33. Zipp F, Weil JG, Einhaupl KM. No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 1999: 5: 964-5.